# Bioavailability of ABT-450 and ABT-267 With Ritonavir

> **NCT02052362** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 16 (actual)

## Conditions studied

- Absolute Bioavailability

## Interventions

- **DRUG:** ABT-450/r/ABT-267

## Key facts

- **NCT ID:** NCT02052362
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2014-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02052362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02052362, "Bioavailability of ABT-450 and ABT-267 With Ritonavir". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT02052362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*